The Avicena Group's extensive product pipeline is comprised of a number of high-value pharmaceutical and OTC candidates that are based on the company's proprietary cellular energy modulation and cellular energy transport platforms. Specifically, the company's candidates have demonstrated the ability to increase, maintain or decrease the flow of cellular energy within the body as necessary. Based on this fundamental control and influence of cellular energy flow, the Avicena Group has compiled a product pipeline with applications in the following areas:
Several of the company's product candidates have demonstrated specific applications in the area of neurodegenerative diseases such as: ALS (Lou Gehrig's disease), Huntington's disease and Parkinson's disease. In scientific studies conducted at leading universities, the Avicena Group's products have been shown to significantly reduce the specific symptoms and/or to significantly delay the progression of these diseases. The company presently has compounds in Phase II or III clinical trials for the treatment of ALS, Huntington's, and Parkinson's disease.
A number of the Avicena Group's product candidates have demonstrated the potential to increase muscle strength and activity. These attributes may position the products as ideal therapies for a variety of neuro-muscluar diseases. The company is presently investigating product candidates as potential therapies for diseases such as Duchenne Muscular Dystrophy (DMD) and Charcot-Marie-Tooth Syndrome (CMT).
A variety of scientific studies have demonstrated the therapeutic and protective skin attributes of the company's Nurigene™ line of skin care products, as well as the company's proprietary dermaceutical ingredient blends. These products and ingredients are formulated to enhance the regeneration of healthy skin and to protect against the effects of aging, as well as oxidative and photo damage.